Paralisia oculomotora que surge de lesões nas vias supranucleares que controlam o movimento extraocular.
Introdução
O que você precisa saber de cara
Paralisia oculomotora que surge de lesões nas vias supranucleares que controlam o movimento extraocular.
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 64 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 112 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
1 gene identificado com associação a esta condição.
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity (PubMed:21985311). The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both (PubMed:21985311, PubMed:32961270). Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isofo
Cytoplasm, cytosolCell membraneCytoplasm, cytoskeletonCell projection, axonCell projection, dendriteSecreted
Variantes genéticas (ClinVar)
152 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
3 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Paralisia oculomotora supranuclear
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Pesquisa e ensaios clínicos
Nenhum ensaio clínico registrado para esta condição.
Publicações mais relevantes
Early clinical characteristics of pathologically confirmed progressive supranuclear palsy and corticobasal degeneration.
Although the clinical features of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are well documented, their early clinical presentations from the perspective of initial clinical consultation remain less well understood. This study aimed to characterize the early clinical features of PSP and CBD to inform clinicians on diagnostic assessment and management strategies. Data were obtained from the National Alzheimer's Coordinating Center (NACC) database (2005-March 2025 data freeze). Neuropathologically confirmed cases of PSP (n = 278) and CBD (n = 149) were included. Analyses were restricted to first clinical visits, focusing on demographic, neuropsychiatric, neurological, and neuropsychological variables. Memory symptoms were reported in more than half of both groups, whereas language impairment was more common in CBD (> 70%) and associated with higher odds of CBD diagnosis. Depression was frequent (~ 50%), with PSP showing higher odds for depressive symptoms but lower odds for disinhibition. Although 20-30% of both PSP and CBD patients exhibited no parkinsonian signs at presentation, gait disturbance, falls, and slowness were common and strongly associated with PSP. Approximately half of both groups presented with cognitive-predominant onset, and nearly one-fifth were initially misdiagnosed as Alzheimer's disease. A substantial proportion of PSP and CBD patients lack parkinsonian signs at first presentation, and cognitive-onset presentations are frequent, leading to early diagnostic uncertainty. Clinicians should recognize these overlapping features when evaluating early atypical parkinsonian or cognitive syndromes.
Hypothalamic atrophy in progressive supranuclear palsy, assessed by convolutional neural network-based automatic segmentation.
The hypothalamus as one of the core structures in metabolic control is increasingly recognized to be morphologically altered in various neurodegenerative diseases. The purpose of this study was to quantitatively investigate the hypothalamic volumes in patients with progressive supranuclear palsy (PSP) and to compare them with controls and Parkinson disease (PD) patients. An automatic hypothalamic volume quantification method based on the use of convolutional neural networks (CNN) of U-Net architecture was applied to the automatic segmentation of the hypothalamus and intracranial volumes (ICV). This CNN-based volumetric analysis was performed in high resolution T1 weighted MRI in two PSP cohorts: cohort A with 78 PSP patients and 63 controls was recorded at 3.0 T at multiple sites; the single site cohort B consisted of 66 PSP patients, 66 PD patients, and 44 controls, recorded at 1.5 T. In cohort A, significant hypothalamic volume reduction was observed in PSP (774 ± 83 mm3) when compared to controls (817 ± 74 mm3). In cohort B, this result of significant hypothalamic volume reduction was confirmed in PSP (745 ± 102 mm3) when compared to controls (831 ± 81 mm3); no significant hypothalamic volume reduction was observed in PD (797 ± 98 mm3), in support of previous studies. The CNN-based hypothalamus volume quantification study demonstrated significantly reduced hypothalamus volumes in PSP patients compared to controls and PD, respectively; future studies will address the metabolic profiles of PSP as potential functional correlates.
Nanoscopic tau aggregates are not shared intermediates but disease-specific entities across tauopathies.
Tauopathies are neurodegenerative diseases marked by pathological tau aggregation. While disease-specific folds of insoluble tau filaments have been established, it remains unclear whether the smaller, earlier species also differ across tauopathies. Here, we characterize these small tau aggregates from postmortem brain of individuals with Alzheimer's disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration, Pick's disease, and healthy controls. Using two complementary single-molecule assays, we confirm that small tau aggregates vary in abundance, morphology, and post-translational modifications. AD features specific long, fibrillar-shaped aggregates enriched in phospho-epitopes, while PSP aggregates are shorter, round, and selectively phosphorylated at serine 356, a site we identify as correlating with markers of inflammation and apoptosis. Aggregate properties co-vary with cellular stress signatures and align with disease-specific seeding profiles, suggesting distinct pathological mechanisms. These findings suggest that small tau aggregates are not a shared intermediate but instead encode disease-specific mechanisms, with potential as both biomarkers and therapeutic targets.
Molecular features of human pathological tau distinguish tauopathy-associated dementias.
In Alzheimer's disease (AD), pathological tau protein shows a progressive accumulation of post-translational modifications (PTMs), reflecting disease severity, progression, and prion-like activity. Although many neurodegenerative diseases with dementia display tau aggregates, the pathological proteoforms of tau protein from each disease type remain unknown. Here, using a quantitative mass spectrometry-based proteomics platform, FLEXITau, deep characterization of pathological tau protein isolated from the brains of 203 human subjects with AD, familial AD (fAD), chronic traumatic encephalopathy (CTE), corticobasal degeneration (CBD), Pick's disease (PiD), progressive supranuclear palsy (PSP), dementia with Lewy bodies (DLB)-a non-tauopathy symptomatic control-and healthy controls (CTR) is performed. Unsupervised data analyses and supervised machine learning identify distinct molecular features of pathological tau for each disease, enabling molecular disease stratification. This study identifies potential disease-specific biomarkers and therapeutic targets for tauopathies and provides critical quantitative information for pharmacokinetic modeling required for therapeutic and disease mechanism studies.
Wernicke's encephalopathy unmasking progressive supranuclear palsy and Alzheimer's pathology: a diagnostic challenge in an older adult.
This case highlights the rare coexistence of Wernicke's encephalopathy, probable progressive supranuclear palsy and probable Alzheimer's disease. The patient presented with acute confusion, repeated falls, postural instability, bradyphrenia, apathy and vertical gaze palsy. Clinical examination raised suspicion of overlapping neurological syndromes. Complementary investigations included brain MRI which revealed periventricular hyperintense regions on T2 and on fluid-attenuated inversion recovery (FLAIR) sequences, suggestive of Wernicke's encephalopathy. A subsequent ioflupane (123I) single-photon emission computed tomography (SPECT) scan showed left-sided dysfunction of presynaptic dopamine transporters, supporting a parkinsonian syndrome. Cerebrospinal fluid biomarkers finally demonstrated elevated total and phosphorylated-tau levels and a decreased Aβ42/Aβ40 ratio, consistent with Alzheimer's pathology. Timely intravenous thiamine was initiated. Once the presumed diagnoses were clinically confirmed, multidisciplinary management was implemented, including physiotherapy and caregiver support.This case illustrates how acute syndromes can unmask or exacerbate chronic neurodegenerative conditions, underscoring, in addition to the need for early intervention, the necessity of a thorough clinical approach. This is especially the case in older adults presenting with complex cognitive and motor symptoms.
Publicações recentes
Vision function in children 10 years after grade 3 or 4 intraventricular haemorrhage with ventricular dilation: A masked prospective study.
Spinocerebellar ataxia type 28 in a Chinese pedigree: A case report and literature review.
[Supranuclear eye movement disorders].
The Non-surgical Management of Ophthalmoplegia.
Supranuclear eye movement disorders.
📚 EuropePMCmostrando 200
Early clinical characteristics of pathologically confirmed progressive supranuclear palsy and corticobasal degeneration.
Journal of neurologyHypothalamic atrophy in progressive supranuclear palsy, assessed by convolutional neural network-based automatic segmentation.
Journal of neurologyLongitudinal monitoring of tau aggregation in progressive supranuclear palsy with [18F]PI-2620 PET.
Alzheimer's & dementia : the journal of the Alzheimer's AssociationA data-driven SSM/PCA analysis approach for differential diagnosis of parkinsonism using 11C-PE2I PET.
NeuroImage. ClinicalNanoscopic tau aggregates are not shared intermediates but disease-specific entities across tauopathies.
Cell reportsMolecular features of human pathological tau distinguish tauopathy-associated dementias.
CellPercutaneous endoscopic gastrostomy in atypical parkinsonian syndromes: survival and aspiration outcomes from a retrospective international cohort.
The New Zealand medical journalPotential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration.
The journal of prevention of Alzheimer's diseaseTreatment of Disturbed Sleep in Progressive Supranuclear Palsy: a randomized, remote, double-blinded, 6-week cross-over design study protocol comparing zolpidem, suvorexant, and placebo.
TrialsWernicke's encephalopathy unmasking progressive supranuclear palsy and Alzheimer's pathology: a diagnostic challenge in an older adult.
BMJ case reportsRefining a mouse model of progressive supranuclear palsy through inoculation of human post-mortem brain-derived tau.
BMC research notesPET evaluation of cholinergic system differences in progressive supranuclear palsy and age-matched controls using [18F]VAT.
Nuclear medicine and biology4R-tau seeding activity reveals molecular subtypes in progressive supranuclear palsy.
Nature communications18 F-FDG, 18 F-FP-CIT, and 18 F-Florzolotau PET Imaging in Progressive Supranuclear Palsy : Region-Specific Correlations Between Glucose Metabolism, Dopaminergic Function, and Tau Pathology.
Clinical nuclear medicineInflammatory and Neurotrophic Factors and Their Connection to Quality of Life in Progressive Supranuclear Palsy-Single-Center Study.
International journal of molecular sciencesWhite matter hyperintensities in the deep cerebral venous territory differ between subcortical and cortical 4-repeat tauopathies.
Parkinsonism & related disordersPlasma NFL, GFAP, sTREM2, pTau231, and clinical severity in progressive supranuclear palsy.
Journal of neurologyDeep Learning-Based Brainstem Segmentation and Multi-Class Classification for Parkinsonian Syndrome.
Journal of magnetic resonance imaging : JMRIDiagnostic utility of biomarkers in progressive supranuclear palsy: toward a biotyping framework.
Journal of neurologyPatient with Progressive Supranuclear Palsy Initially Diagnosed as Anxiety and Depression.
Revista Colombiana de psiquiatriaPlasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease.
NeurologyComparative [18F]Florzolotau and [18F]FDG PET Imaging Patterns in Anti-IgLON5 Disease and Progressive Supranuclear Palsy.
Clinical nuclear medicinePatterns of Longitudinal Regional Brain Atrophy in Patients With Different Progressive Supranuclear Palsy Clinical Variants.
NeurologyDynamic multi-scale deep learning with mixture of experts for differentiating iNPH and PSP using MRI.
International journal of computer assisted radiology and surgeryMovement Disorders and Oculomotor Abnormalities in Whipple's Disease: An Updated Systematic Review.
Tremor and other hyperkinetic movements (New York, N.Y.)Automated MRI-Based Classification of Parkinsonism: A Deep Learning Approach to Distinguish PD From PSP.
CNS neuroscience & therapeuticsDeep transcranial magnetic stimulation in progressive supranuclear palsy: a randomized double-blind, cross-over study.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyLevodopa exposure and nigral neuroinflammation in parkinsonian disorders: A postmortem study of 63 cases.
Scientific reportsData-Driven differentiation of idiopathic Normal-Pressure hydrocephalus and progressive supranuclear palsy via automated volumetric analysis.
NeuroradiologyThe discriminative linguistic profiles of progressive supranuclear palsy and Parkinson's disease.
NeurologiaSleep phenotypes of α-synucleinopathies and tauopathies with Parkinsonism.
Parkinsonism & related disordersLeveraging Proteomics to Explore the Molecular Mechanisms of Primary Tauopathies.
Journal of neurochemistryHybrid Tau-PET/MRI study: Quantitative susceptibility mapping in progressive supranuclear palsy and its correlation with Tau-PET.
European journal of nuclear medicine and molecular imagingSpatial Metabolic Covariance Networks in Progressive Supranuclear Palsy: Implications for Symptomatology and Their Neural Basis.
Movement disorders : official journal of the Movement Disorder SocietyDeceleration Capacity as a Marker of Autonomic Cardiac Modulation in Prodromal and Manifest Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy.
European journal of neurologyBarcelona Progressive Supranuclear Palsy (PSP) Registry: Clinical, Oculomotor, and Cerebrospinal Fluid Markers; from Suggestive to Definite Cases.
Movement disorders : official journal of the Movement Disorder SocietyA Mathematical Model of Cellular Aggregation Predicts Patterns of Tau Accumulation in Neurodegenerative Disease.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)Progressive supranuclear palsy against everyone else: a look into the specificity of MRI markers.
Journal of the neurological sciencesInvestigating the impact of white matter hyperintensities on longitudinal progression in progressive supranuclear palsy.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyEarly subtypes and progressions of progressive supranuclear palsy: a data-driven brain bank study.
Journal of neurologyCentral eye movement abnormalities in patients with SMA types II and III.
Neurophysiologie clinique = Clinical neurophysiologyBrain linear measurement index in the differential diagnosis between idiopathic normal pressure hydrocephalus and progressive supranuclear palsy.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyNo anti-IgLON5 antibody in carefully diagnosed PSP patients with "atypical" or variant clinical features.
Parkinsonism & related disordersA novel lncRNA FAM151B-DT regulates degradation of aggregation prone proteins.
Molecular psychiatryVisual interpretation of [18F]Florzolotau Tau-PET imaging for differentiating alzheimer's disease and progressive supranuclear palsy.
European journal of nuclear medicine and molecular imagingAZP2006 in Progressive Supranuclear Palsy: Outcomes from a Phase 2a Multicenter, Randomized Trial, and Open-Label Extension on Safety, Biomarkers, and Disease Progression.
Movement disorders : official journal of the Movement Disorder SocietyDynamic Stability Analysis of Progressive Supranuclear Palsy Affected Gait Using Lyapunov Floquet Theory.
IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology SocietyThe Progressive Supranuclear Palsy Clinical Deficits Scale accurately reflects functional as well as patient- and caregiver-reported outcomes.
Parkinsonism & related disordersNeuroanatomical normative modelling in frontotemporal lobar degeneration: higher heterogeneity in the behavioural variant.
Journal of neurologyElevated levels of cerebrospinal fluid soluble triggering receptor expressed on myeloid cells 2 in multiple system atrophy: a marker of disease-associated microglial activation.
Journal of neural transmission (Vienna, Austria : 1996)Low synaptic and neurosecretory proteins in cerebrospinal fluid in early parkinsonian disease.
Journal of the neurological sciencesAtypical parkinsonian syndromes in French Guiana: Similarities and differences with Caribbean variants.
Journal of Parkinson's diseaseQuantitative Susceptibility Mapping and Iron Deposition in Autopsy-Confirmed Progressive Supranuclear Palsy.
Movement disorders clinical practiceCircadian Rhythms of Sleep-Wake, Thermoregulatory and Cardiovascular Function in Progressive Supranuclear Palsy.
Movement disorders clinical practiceA Review of FDG-PET in Progressive Supranuclear Palsy and Corticobasal Syndrome.
International journal of molecular sciencesMidsagittal Midbrain Area and Midbrain-to-Pons-Ratio Cannot Distinguish Overlap Syndromes Between Amyotrophic Lateral Sclerosis and Progressive Supranuclear Palsy.
Clinical neuroradiologyPrevalence and correlated factors of REM sleep behavior disorder in patients with progressive supranuclear palsy.
Sleep medicineProgressive Supranuclear Palsy-A Global Review.
Movement disorders clinical practiceMultimodal MRI biomarkers optimize differentiation between progressive supranuclear palsy and Parkinson's disease.
Neurobiology of diseaseAlzheimer's disease traits in Parkinson's disease without α-synuclein seeding.
Alzheimer's & dementia : the journal of the Alzheimer's AssociationBrain Atrophy Does Not Predict Clinical Progression in Progressive Supranuclear Palsy.
Movement disorders : official journal of the Movement Disorder SocietyPrevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals.
Movement disorders : official journal of the Movement Disorder SocietyComparison of Two α-Synuclein Seed Amplification Assays for Discrimination of Parkinson Disease and Atypical Parkinsonism.
Movement disorders : official journal of the Movement Disorder SocietyArtificial Intelligence Diagnosis of Ocular Motility Disorders From Clinical Videos.
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology SocietyDifferences in neuropsychological performance across clinical variants of progressive supranuclear palsy.
Journal of the International Neuropsychological Society : JINSRole of 18F-florzolotau PET in diagnostic and therapeutic decision-making for cognitive impairment.
Alzheimer's & dementia : the journal of the Alzheimer's AssociationMotor and non-motor features in progressive supranuclear palsy: the impact of microtubule associated protein tau haplotypes among a Tunisian cohort.
Journal of neural transmission (Vienna, Austria : 1996)Cryo-EM structure of the vault from human brain reveals symmetry mismatch at its caps.
Structure (London, England : 1993)Pilot Study of [11C]HY-2-15: A Mixed Alpha-Synuclein and Tau PET Radiotracer.
CellsMagnetic Resonance Imaging of Extra Ocular Muscles and Oculomotor Nerves in Patients with Congenital Monocular Elevation Deficit.
Journal of binocular vision and ocular motilityRelationships between neuronal loss, age of death, disease duration and MRI brain volumes in progressive supranuclear palsy.
Parkinsonism & related disordersAn Exploratory Analysis of Differential Tear Fluid miRNAs in Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes.
Molecular neurobiologyProgressive Supranuclear Palsy and Corticobasal Syndrome.
Continuum (Minneapolis, Minn.)Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and safety of oral atomoxetine for treating cognitive and behavioural changes in people with progressive supranuclear palsy syndromes in the UK.
BMJ openThe Progression of NUS1-Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR.
CNS neuroscience & therapeuticsDiagnostic utility of tectal plate measures in clinical variants of progressive supranuclear palsy.
Journal of neurologyMachine learning approach effectively discriminates between Parkinson's disease and progressive supranuclear palsy: Multi-level indices of rs-fMRI.
Brain research bulletinA Comparative Analysis of Different MRI Sequences Dedicated for Invivo Detection of Mineralization in a Single Large Cohort of Progressive Supranuclear Palsy and Healthy Controls.
Neurology IndiaIn search of the optimal MRI marker for progressive supranuclear palsy: a large, single-center, retrospective study on the effect of phenotype, diagnostic certainty and disease duration.
Journal of neurologyLanguage impairment is associated with faster progression in progressive supranuclear palsy-Richardson syndrome.
Alzheimer's & dementia : the journal of the Alzheimer's AssociationThe role of blood-based biomarkers in Parkinsonian disorders, Alzheimer's disease and frontotemporal dementia.
Journal of the neurological sciencesEvidence for trans-synaptic propagation of oligomeric tau in human progressive supranuclear palsy.
Nature neuroscienceBedside Assessment of Downgaze Limit by Amplitude.
Movement disorders clinical practiceFrontotemporal Lobar degeneration with TDP-43 presenting as progressive supranuclear palsy syndrome.
Acta neuropathologica communicationsDifferences in the Regional T1/T2-Weighted Ratio Index Between Healthy Controls and Patients With Progressive Supranuclear Palsy.
Psychogeriatrics : the official journal of the Japanese Psychogeriatric SocietyDorsal hyperintensity and iron deposition patterns in the substantia nigra of Parkinson's disease, idiopathic REM sleep behavior disorder, and Parkinson-plus syndromes at 7T MRI: a prospective diagnostic study.
Translational neurodegenerationTau positron emission tomography in the Parkinson and Richardson subtypes of progressive supranuclear palsy.
Parkinsonism & related disordersCan Language Characteristics Contribute to the Classification of Neurodegenerative Disorders? -An Exploratory Study.
Internal medicine (Tokyo, Japan)Progression and natural history of Atypical Parkinsonism (ATPARK): Protocol for a longitudinal follow-up study from an underrepresented population.
PloS oneBrain Microstructure Interrogation by Diffusion Tensor and Kurtosis Imaging in Progressive Supranuclear Palsy Subtypes.
Journal of neuroimaging : official journal of the American Society of NeuroimagingDifferences in the soluble and insoluble proteome between primary tauopathies.
Alzheimer's & dementia : the journal of the Alzheimer's AssociationSpectral domain and angiography optical coherence tomography in atypical parkinsonisms and Parkinson disease: an explorative study.
Parkinsonism & related disordersDiagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study.
The Lancet. NeurologyRehabilitation of Vertical Gaze Palsy and Impaired Eye Proprioception Following Bilateral Thalamic Infarcts: A Case Report.
NeuroRehabilitationThe Impact of Neuropsychiatric Symptoms in Perceived Quality of Life in Patients With Progressive Supranuclear Palsy.
European journal of neurologyDiffusion Tensor Imaging in Progressive Supranuclear Palsy Versus Other Neurodegenerative Diseases: A Review.
Journal of neuroimaging : official journal of the American Society of NeuroimagingThe potential of proteomics for in-depth molecular investigations of progressive supranuclear palsy.
Expert review of proteomicsClinical Diagnosis of Progressive Supranuclear Palsy (PSP): A Clinicopathological Comparison of Patients with Confirmed PSP and Clinical Mimics.
Movement disorders : official journal of the Movement Disorder SocietyUncovering Image-Driven Subtypes with Distinct Pathology and Clinical Course in Autopsy-Confirmed Four Repeat Tauopathies.
Annals of neurologyBrain Networks Route Neurodegeneration Patterns in Patients with Progressive Supranuclear Palsy.
Movement disorders : official journal of the Movement Disorder SocietyFeasibility of expiratory muscle strength training in individuals with progressive supranuclear palsy.
Neurodegenerative disease managementMultifactorial etiology of progressive supranuclear palsy (PSP): the genetic component.
Acta neuropathologicaTackling gender in progressive supranuclear palsy: Male patients present more apathy.
Journal of Parkinson's diseaseMachine Learning Models of Voxel-Level [18F] Fluorodeoxyglucose Positron Emission Tomography Data Excel at Predicting Progressive Supranuclear Palsy Pathology.
Annals of neurologyMagnetic Susceptibility and Area in the Subthalamic Nucleus Measured by QSM for Diagnosis of Progressive Supranuclear Palsy.
Movement disorders clinical practiceAssociations between neuropsychological profile and regional brain FDG uptake in progressive supranuclear palsy.
Journal of Parkinson's diseaseChoroid plexus enlargement correlates with subcortical tau deposition in progressive supranuclear palsy.
Fluids and barriers of the CNS[An autopsy case of a 76-year-old woman with progressive supranuclear palsy initially presenting with dropped head and clinical features of pure akinesia with gait freezing].
Rinsho shinkeigaku = Clinical neurologyComparative study of nonmotor symptoms in progressive supranuclear palsy and Parkinson's disease.
BMC neurologyEvaluating the Homogeneity of the PSP-RS Syndrome beyond Core Features.
Movement disorders clinical practiceA Spanish-Portuguese GWAS of progressive supranuclear palsy reveals a novel risk locus in NFASC.
European journal of human genetics : EJHGImpact of gene-gene interactions in Progressive Supranuclear Palsy: new genetic perspectives in the Asian-Indian population.
Journal of neurogeneticsThe Genetic Background of the Immunological and Inflammatory Aspects of Progressive Supranuclear Palsy.
International journal of molecular sciencesNeurophysiology of Atypical Parkinsonian Syndromes: A Study Group Position Paper.
Movement disorders : official journal of the Movement Disorder Society[Oculomotor disorders in patients with amyotrophic lateral sclerosis].
Zhurnal nevrologii i psikhiatrii imeni S.S. KorsakovaHigh rates of diagnostic discordance and co-pathology: Insights into PSP from the NACC dataset.
Alzheimer's & dementia : the journal of the Alzheimer's AssociationIdentifying Common Disease Trajectories of Progressive Supranuclear Palsy with Electronic Health Records.
Movement disorders clinical practicePhenotypic variants of progressive supranuclear palsy in a real-world dataset as identified by existing algorithms.
Journal of the neurological sciencesNeuronally-Derived Extracellular Vesicles Transforming Growth Factor Beta-1 Levels in Progressive Supranuclear Palsy.
Movement disorders : official journal of the Movement Disorder SocietyCharacterizing the expression profile of 3R tau pathology in Pick's disease.
Science advancesConcomitant progressive supranuclear palsy and multiple system atrophy: A rare case report of tauopathy and synucleinopathy interface.
Journal of neuroradiology = Journal de neuroradiologieAssociation between adiponectin and lipids in Parkinson's disease.
Clinical neurology and neurosurgeryDifferentiating Progressive Supranuclear Palsy and Corticobasal Syndrome: Insights from Cerebrospinal Fluid Biomarkers-A Narrative Review.
Medicina (Kaunas, Lithuania)Argyrophilic Grain Disease Clinically Presenting as Progressive Supranuclear Palsy with Progressive Gait Freezing.
Movement disorders clinical practiceCell-specific mitochondrial response in progressive supranuclear palsy.
MitochondrionA radiomics approach to distinguish Progressive Supranuclear Palsy Richardson's syndrome from other phenotypes starting from MR images.
Computer methods and programs in biomedicineTongue strength in progressive supranuclear palsy.
Parkinsonism & related disordersCognitive and neuropsychiatric profiles distinguish atypical parkinsonian syndromes.
Brain : a journal of neurologyMidbrain cytotoxic T cells as a distinct neuropathological feature of progressive supranuclear palsy.
Brain : a journal of neurologyAtypical Parkinsonian Disorders.
Neurologic clinicsPlasma miRNA Biomarker Signatures in Parkinsonian Syndromes.
Molecular neurobiologyEvaluating the diagnostic performance of six plasma biomarkers for Alzheimer's disease and other neurodegenerative dementias in a large Chinese cohort.
Alzheimer's research & therapyCerebrospinal fluid and blood neurofilament light chain in Parkinson's disease and atypical parkinsonian syndromes: a systematic review and Bayesian network meta-analysis.
Journal of neurologySupranuclear Disorders of Eye Movements.
Continuum (Minneapolis, Minn.)I-Beam Sign in Progressive Supranuclear Palsy.
Neurology IndiaDoes Midbrain Atrophy Distinguish Progressive Supranuclear Palsy from Frontotemporal Dementia?
Movement disorders clinical practiceNeuropsychiatric symptoms in sporadic Creutzfeldt-Jakob disease.
Brain : a journal of neurologyAZP2006 (Ezeprogind®): a Promising New Drug Candidate in the Battle Against Neurodegenerative Diseases.
ChemMedChemNovel blood-based proteomic signatures across multiple neurodegenerative diseases.
Alzheimer's & dementia : the journal of the Alzheimer's AssociationInvestigation of the significance of quantitative MRI parameters in differentiating PSP from MSA patients.
Neurodegenerative disease managementAnalysis of C9orf72 repeat length in progressive supranuclear palsy, corticobasal syndrome, corticobasal degeneration, and atypical parkinsonism.
Journal of neurologyGeometry based prediction of tau protein sites and motifs associated with misfolding and aggregation.
Scientific reportsInvestigation of the HLA locus in autopsy-confirmed progressive supranuclear palsy.
ImmunobiologyDeep brain stimulation in progressive supranuclear palsy: a dead-end story? A narrative review.
Journal of neural transmission (Vienna, Austria : 1996)Binocular diplopia: a retrospective study of 204 cases.
NeurologiaAutomated Imaging Differentiation for Parkinsonism.
JAMA neurologyProbe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies.
Molecular neurodegenerationJoint examination of reflexive vertical saccades and small involuntary fixational saccades improves the classification of patients with progressive supranuclear palsy (PSP): a ROC study.
Experimental brain researchRadiosynthesis, In Vitro Characterization, and In Vivo PET Neuroimaging of [18F]F-4 for Tau Protein: A First-in-Human PET Study.
ACS chemical neuroscienceCopy Number Variation and Haplotype Analysis of 17q21.31 Reveals Increased Risk Associated with Progressive Supranuclear Palsy and Gene Expression Changes in Neuronal Cells.
Movement disorders : official journal of the Movement Disorder SocietyThe longitudinal study of morphometric measurement changes in progressive supranuclear palsy.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International ConferenceA case report of palatal tremor in progressive supranuclear palsy.
Parkinsonism & related disordersPost-mortem validation of in vivo TSPO PET as a microglial biomarker.
Brain : a journal of neurologyTaste impairment in patients with Parkinsonism.
Journal of neurologyAssessment of Piezo1 Expression in Urinary Exfoliated Cells as a Diagnostic Indicator for Multiple System Atrophy.
Movement disorders : official journal of the Movement Disorder SocietyAnnual percentage change of MR Parkinsonism index in progressive supranuclear palsy: a feasibility study.
European radiologySubcortical tau burden correlates with regional brain atrophy and plasma markers in four-repeat tauopathy parkinsonism.
Journal of Parkinson's diseaseGABAergic modulation of beta power enhances motor adaptation in frontotemporal lobar degeneration.
Alzheimer's & dementia : the journal of the Alzheimer's AssociationEye movement disorders in genetic dystonia syndromes: A literature overview.
Parkinsonism & related disordersRelationships Between Glymphatic System Activity and Tau Burden, Dopaminergic Impairment, Abnormal Glucose Metabolism in Progressive Supranuclear Palsy.
CNS neuroscience & therapeuticsClinical prognostic factors in progressive supranuclear palsy: Implications for clinical trials.
Journal of Parkinson's diseaseOverlap in the diagnostic criteria of frontotemporal dementia syndromes with parkinsonism.
Journal of Alzheimer's disease : JADPathomechanisms of neuropsychiatric disturbances in atypical parkinsonian disorders: a current view.
Journal of neural transmission (Vienna, Austria : 1996)Self-Reported REM Sleep Behavior Disorder in Patients With Progressive Supranuclear Palsy: Clinical and 18F-Florzolotau PET Imaging Findings.
NeurologyNigral Neuroinflammation and Dopaminergic Neurons in Parkinson's Disease and Atypical Parkinsonisms.
Annals of neurologyMultimodality Brain Imaging Markers in Progressive Supranuclear Palsy Subtypes and Parkinson's Disease.
Movement disorders clinical practiceBowing Index in Individuals With Parkinson's Disease, Progressive Supranuclear Palsy, and Ataxia.
The LaryngoscopeApplication of elastic net for clinical outcome prediction and classification in progressive supranuclear palsy: A multicenter cohort study.
Parkinsonism & related disordersModeling Sporadic Progressive Supranuclear Palsy in 3D Midbrain Organoids: Recapitulating Disease Features for In Vitro Diagnosis and Drug Discovery.
Annals of neurologyA Short Cognitive and Neuropsychiatric Assessment Scale for Progressive Supranuclear Palsy.
Movement disorders clinical practiceFrequency of anti-IgLON5 disease in patients with a typical clinical presentation of progressive supranuclear palsy/corticobasal syndrome.
Parkinsonism & related disordersThe Value of Quantitative Susceptibility Mapping and Morphometry in the Differential Diagnosis of Parkinsonism.
AJNR. American journal of neuroradiologyProgressive supranuclear palsy: an updated approach on diagnosis, treatment, risk factors and outlook in Mexico.
Gaceta medica de MexicoAssisted Parkinsonism Diagnosis Using Multimodal MRI-The Role of Clinical Insights.
Brain and behaviorIdiopathic normal pressure hydrocephalus concomitant with progressive supranuclear palsy.
Parkinsonism & related disordersLongitudinal assessment of white matter alterations in progressive supranuclear palsy variants using diffusion tractography.
Parkinsonism & related disordersBrain-derived tau oligomer polymorphs: distinct aggregations, stability profiles, and biological activities.
Communications biologyProspective Multicenter Evaluation of the MDS "Suggestive of PSP" Diagnostic Criteria.
Movement disorders : official journal of the Movement Disorder SocietyA smart tool for non expert clinicians for the dissemination of the MDS criteria for progressive supranuclear palsy.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical NeurophysiologyA subgroup of multiple system atrophy with rapid decline in vital capacity.
Journal of the neurological sciencesA 15-Item modification of the PSP rating scale to improve clinical meaningfulness and statistical performance.
Nature communicationsOral applause sign in progressive supranuclear palsy.
Cortex; a journal devoted to the study of the nervous system and behaviorRapid Cognitive Deterioration in Progressive Supranuclear Palsy: A 1-Year Follow-Up Study.
Movement disorders clinical practiceIron(ing) out parkinsonisms: The interplay of proteinopathy and ferroptosis in Parkinson's disease and tau-related parkinsonisms.
Redox biologyFlattened red nucleus in progressive supranuclear palsy detected by quantitative susceptibility mapping.
Parkinsonism & related disordersFunctional connectivity abnormalities in clinical variants of progressive supranuclear palsy.
NeuroImage. ClinicalThe Effect of Alcohol Consumption on Progressive Supranuclear Palsy: A Cross-Sectional Study.
CNS neuroscience & therapeuticsClinical trial eligibility in PSP: Population representativeness and potential criteria adjustment based on PSP-NET findings.
Parkinsonism & related disordersPrediagnostic Phase of Progressive Supranuclear Palsy in a Longitudinal Epidemiological Study of Dementia and Aging.
Internal medicine (Tokyo, Japan)Utility of Cerebrospinal Fluid Transferrin Receptor per Ferritin Ratio in Progressive Supranuclear Palsy.
Movement disorders clinical practicePossible Impact of Peripheral Inflammatory Factors and Interleukin-1β (IL-1β) on Cognitive Functioning in Progressive Supranuclear Palsy-Richardson Syndrome (PSP-RS) and Progressive Supranuclear Palsy-Predominant Parkinsonism (PSP-P).
International journal of molecular sciencesCarnitine supplementation in progressive supranuclear palsy.
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral NutritionPost mortem validation and mechanistic study of UCB-J in progressive supranuclear palsy patients' brains.
Alzheimer's & dementia : the journal of the Alzheimer's AssociationMRI classification of progressive supranuclear palsy, Parkinson disease and controls using deep learning and machine learning algorithms for the identification of regions and tracts of interest as potential biomarkers.
Computers in biology and medicineVideo-Oculography for Enhancing the Diagnostic Accuracy of Early Oculomotor Dysfunction in Progressive Supranuclear Palsy.
Journal of movement disordersSingle-cell transcriptomic and neuropathologic analysis reveals dysregulation of the integrated stress response in progressive supranuclear palsy.
Acta neuropathologicaA common marker of affect recognition dysfunction in the FTD spectrum of disorders.
European journal of neurologySpatial discrimination in patients with MSA, PSP, DIP, and VP with pain.
Scientific reportsDifferentiating atypical parkinsonian syndromes with hyperbolic few-shot contrastive learning.
NeuroImageTransdiagnostic Network Localization of Social, Language, and Motor Symptoms in Patients With Frontotemporal Lobar Degeneration.
NeurologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Paralisia oculomotora supranuclear.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Paralisia oculomotora supranuclear
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Early clinical characteristics of pathologically confirmed progressive supranuclear palsy and corticobasal degeneration.
- Hypothalamic atrophy in progressive supranuclear palsy, assessed by convolutional neural network-based automatic segmentation.
- Nanoscopic tau aggregates are not shared intermediates but disease-specific entities across tauopathies.
- Molecular features of human pathological tau distinguish tauopathy-associated dementias.
- Wernicke's encephalopathy unmasking progressive supranuclear palsy and Alzheimer's pathology: a diagnostic challenge in an older adult.
- Vision function in children 10 years after grade 3 or 4 intraventricular haemorrhage with ventricular dilation: A masked prospective study.
- Spinocerebellar ataxia type 28 in a Chinese pedigree: A case report and literature review.
- [Supranuclear eye movement disorders].
- The Non-surgical Management of Ophthalmoplegia.
- Supranuclear eye movement disorders.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:98687(Orphanet)
- MONDO:0020257(MONDO)
- GARD:19546(GARD (NIH))
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Q55789251(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
